This preplanned subset analysis of the phase III MONET1 study aimed to determine whether motesanib combined with carboplatin/paclitaxel ( C/P ) would result in improved overall survival ( OS ) versus chemotherapy alone , in a subset of Asian patients with nonsquamous nonsmall-cell lung cancer ( NSCLC ) .